AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Crescent Biopharma Partners with Kelun-Biotech for Oncology Therapeutics, Raises $185M
ByAinvest
Thursday, Dec 4, 2025 8:36 am ET1min read
Crescent Biopharma has partnered with Sichuan Kelun-Biotech to develop and commercialize oncology therapeutics. The deal includes exclusive rights for each company to develop and commercialize their respective candidates in specific markets. Crescent will receive an $80 million upfront payment and up to $30 million in milestones, while Kelun-Biotech will receive a $20 million upfront payment and up to $1.25 billion in milestones. The partnership also includes the development of both candidates as monotherapies and evaluation of CR-001 in combination with SKB105.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet